Overview

Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events

Status:
Terminated
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This study is being carried out to study the efficacy and safety of treatment with melagatran injection followed by ximelagatran tablets in preventing blood clots, compared with enoxaparin for a period of 5-6 weeks. A separate visit, independent from the study will be done approximately 6 months after the surgery.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Melagatran
Ximelagatran